Closed-Loop Glucagon Administration For Hypoglycemia Treatment

Exclusion Criteria

• •Unable to provide informed consent.
• •Unable to comply with study procedures.
• •Current participation in another diabetes-related clinical trial other than one that is primarily observational in nature.
• •Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception
• •History of cystic fibrosis, pancreatitis, or other pancreatic disease other than type 1 diabetes
• •End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).
• •Any known liver or biliary disease including cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, any form of viral hepatitis.
• •Congestive heart failure (established history of CHF, paroxysmal nocturnal dyspnea, or orthopnea).
• •Acute illness or exacerbation of chronic illness at the time of the study.
• •Seizure disorder or history of hypoglycemic seizure in the last 1 year
• •History of pheochromocytoma. Fractionated metanephrines will be tested in patients with history increasing the risk for a catecholamine secreting tumor:
• •Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year).
• •Current alcohol abuse (intake averaging \> 3 drinks daily in last 30 days) or substance abuse (any use within the last 6 months of controlled substances without a prescription).
• •Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference.
• •History of adverse reaction to glucagon (including allergy) besides nausea and vomiting.
• •Unwilling or unable to completely avoid acetaminophen during the study period.
• •Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study procedures.